Treatment and blinatumomab responses
| . | Before blinatumomab . | After blinatumomab . | ||
|---|---|---|---|---|
| . | Treatment . | MRD . | Treatment . | MRD . |
| Case 1 | VCR/pred × 2 wk | 8% (predose escalation) | Low-dose oral mercaptopurine+IT Ara-C | Negative after cycle 2 |
| Case 2 | 4 drug induction* | 1.9% | Haploidentical BMT | Negative |
| . | Before blinatumomab . | After blinatumomab . | ||
|---|---|---|---|---|
| . | Treatment . | MRD . | Treatment . | MRD . |
| Case 1 | VCR/pred × 2 wk | 8% (predose escalation) | Low-dose oral mercaptopurine+IT Ara-C | Negative after cycle 2 |
| Case 2 | 4 drug induction* | 1.9% | Haploidentical BMT | Negative |
Ara-C, cytosine arabinoside; BMT, bone marrow transplant; IT, intrathecal; pred, prednisone; VCR, vincristine.
4-drug induction, regimen B of UKALL2019 protocol.12